6,500 Shares in Celcuity, Inc. $CELC Purchased by SBI Okasan Asset Management Co.Ltd.

SBI Okasan Asset Management Co.Ltd. purchased a new position in shares of Celcuity, Inc. (NASDAQ:CELC) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 6,500 shares of the company’s stock, valued at approximately $660,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CELC. Apis Capital Advisors LLC acquired a new position in Celcuity during the third quarter worth about $38,334,000. UBS Group AG grew its stake in shares of Celcuity by 910.1% in the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after buying an additional 769,891 shares during the period. Deerfield Management Company L.P. purchased a new stake in shares of Celcuity in the 3rd quarter valued at approximately $36,236,000. Alliancebernstein L.P. grew its stake in shares of Celcuity by 2,208.6% in the 3rd quarter. Alliancebernstein L.P. now owns 652,649 shares of the company’s stock valued at $32,241,000 after buying an additional 624,379 shares during the period. Finally, Soleus Capital Management L.P. increased its holdings in shares of Celcuity by 17.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after buying an additional 437,696 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Stock Performance

Shares of CELC stock opened at $132.88 on Friday. The firm’s 50 day moving average price is $123.09 and its 200-day moving average price is $110.94. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. Celcuity, Inc. has a one year low of $10.50 and a one year high of $151.02. The firm has a market cap of $6.48 billion, a P/E ratio of -34.07 and a beta of 0.09.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, equities research analysts predict that Celcuity, Inc. will post -3.96 EPS for the current year.

Insider Activity at Celcuity

In other news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. This represents a 57.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the transaction, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This represents a 27.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 37,000 shares of company stock worth $5,111,950. Company insiders own 13.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CELC. Citizens Jmp lifted their price target on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a research report on Monday, May 4th. HC Wainwright lifted their price target on shares of Celcuity from $165.00 to $185.00 and gave the company a “buy” rating in a research report on Monday, May 18th. Stifel Nicolaus set a $150.00 price target on shares of Celcuity in a research report on Monday, May 4th. Macquarie Infrastructure set a $160.00 price target on shares of Celcuity in a research report on Thursday. Finally, Wolfe Research reaffirmed an “outperform” rating and set a $110.00 price target on shares of Celcuity in a research report on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Celcuity has a consensus rating of “Moderate Buy” and a consensus price target of $150.27.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.